Company logo

LGVN - Longeveron Inc.

NASDAQ -> Healthcare -> Biotechnology
Miami, United States
Type: Equity

LGVN price evolution
LGVN
(in millions $) 1 May 2024 31 Jan 2024 30 Oct 2023 30 Jul 2023
Current assets
Cash
Short term investments
Net receivables $0.18 $0.11 $0.1 $0.1
Inventory
Total current assets $3.76 $5.85 $5.04 $10.29
Long term investments
Property, plant & equipment $3.49 $3.75 $3.85 $4.1
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $9.7 $12.08 $11.63 $17.09
Current liabilities
Accounts payable $1.47 $0.64 $0.83 $1.7
Deferred revenue
Short long term debt
Total current liabilities $5.29 $3.89 $3.39 $4.08
Long term debt
Total noncurrent liabilities
Total debt
Total liabilities $6.66 $5.34 $4.99 $5.83
Shareholders' equity
Retained earnings -$89.04 -$84.98 -$78.96 -$73.05
Other shareholder equity $0 -$0.1 -$0.41 -$0.43
Total shareholder equity
(in millions $) 31 Jan 2024 31 Jan 2023 31 Jan 2022 30 Jan 2021
Current assets
Cash $0.82
Short term investments
Net receivables $0.11 $0.22 $0.06 $0.42
Inventory
Total current assets $5.85 $20.28 $35.38 $1.85
Long term investments
Property, plant & equipment $3.75 $4.48 $4.88 $3.6
Goodwill & intangible assets
Total noncurrent assets $7.39
Total investments
Total assets $12.08 $27.41 $42.77 $9.24
Current liabilities
Accounts payable $0.64 $1.75 $0.65 $1.59
Deferred revenue $0.01
Short long term debt
Total current liabilities $3.89 $4.87 $2.71 $3.83
Long term debt $0.31
Total noncurrent liabilities $3.45
Total debt
Total liabilities $5.34 $6.91 $5.31 $7.28
Shareholders' equity
Retained earnings -$84.98 -$62.77 -$43.94
Other shareholder equity -$0.1 -$0.46 -$0.1 $1.96
Total shareholder equity
(in millions $) 30 Oct 2022 30 Jul 2022 1 May 2022 31 Jan 2022
Revenue
Total revenue $0.47 $0.37
Cost of revenue
Gross Profit $0.16 $0.3
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $4.38 $3.69
Operating income
Income from continuing operations
EBIT
Income tax expense
Interest expense -$0.1 -$0.1
Net income
Net income -$5.62 -$3.51
Income (for common shares)
(in millions $) 31 Jan 2022 30 Jan 2021 30 Jan 2020 31 Jan 2019
Revenue
Total revenue $1.31 $5.63 $5.64 $2.13
Cost of revenue
Gross Profit $0.59 $1.83 $1.75 $0.68
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $18.04 $6.41 $5.64 $7.05
Operating income -$3.78 -$3
Income from continuing operations
EBIT
Income tax expense
Interest expense $0.01 $0 $0.02
Net income
Net income -$17.05 -$3.72 -$2.96 -$6.34
Income (for common shares)
(in millions $) 30 Oct 2022 30 Jul 2022 1 May 2022 31 Jan 2022
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$0.11 $2.28 $0.77 -$10.7
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing -$0.32 -$0.29 -$0.14 $45.17
Effect of exchange rate
Change in cash and equivalents -$12.08 -$5.43 -$3.52 $24.83
(in millions $) 31 Jan 2022 30 Jan 2021 30 Jan 2020 31 Jan 2019
Net income -$3.72 -$2.96
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$2.36 -$2.39
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$10.7 -$0.26 -$0.13 -$0.21
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $45.17 $1.58 $0.35 $1.36
Effect of exchange rate
Change in cash and equivalents $24.83 -$1.05 -$2.17 -$4.03
Fundamentals
Market cap $9.80M
Enterprise value N/A
Shares outstanding 2.52M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio 0.71
Quick ratio N/A